Senti Biosciences Holdings, Inc.
SNTI Nasdaq
SEC CIK 1854270
Follow Senti Biosciences
Weekly email: filings, results
Revenue, last quarter
$19K
Net income
−$11.6M
+36.1% vs same quarter last year
EPS, diluted
−$0.37
+46.4% vs same quarter last year
Operating cash flow
−$6.7M
+28.8% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $22K | −$61.4M |
| FY24 | $0 | −$52.8M |
| FY23 | $2M | −$71.1M |
| FY22 | $3.3M | −$58.2M |
| FY21 | $2.3M | −$55.3M |
| FY20 | - | - |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | −312631.8% | −279263.6% |
| FY24 | - | - |
| FY23 | −4687.9% | −3592.4% |
| FY22 | −1889.3% | −1771.5% |
| FY21 | −1765.4% | −2414.6% |
| FY20 | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$43.6M |
| FY24 | −$41.4M |
| FY23 | −$64.4M |
| FY22 | −$76.3M |
| FY21 | −$40.2M |
| FY20 | - |
- Senti Biosciences
- Healthcare median
Show the numbers
| Year | Senti Biosciences | Healthcare median |
|---|---|---|
| FY25 | −279263.6% | −30.6% |
| FY24 | - | −47% |
| FY23 | −3592.4% | −58% |
| FY22 | −1771.5% | −80.4% |
| FY21 | −2414.6% | −71.9% |
| FY20 | - | −62.2% |